Cancer remains a leading cause of death worldwide, and a major limitation of current oncologic therapies is the lack of specificity of both chemotherapeutic and imaging agents. This deficiency contributes to suboptimal antitumor efficacy and significant systemic toxicity. The review frames this problem as a delivery barrier that must be overcome to improve therapeutic index and enable precision oncology.
Magnetic nanomaterials, particularly iron oxide–based particles such as Fe3O4 (magnetite) and maghemite (γ-Fe2O3), have attracted attention as multifunctional platforms. Two classes emphasized are Superparamagnetic Iron Oxide Nanoparticles (SPION) and Ultrasmall Superparamagnetic Iron Oxide Nanoparticles (USPION). Key advantageous properties include magnetic responsiveness and biocompatibility, enabling integration of multiple functions—diagnostic imaging, targeted delivery, hyperthermia, and drug release—within a single material. These combined modalities permit imaging, therapy, and monitoring from the same platform, which is central to theranostic approaches.
Recent progress in the field includes methods for synthesis and rigorous physicochemical characterization to optimize biological performance. Surface engineering with biocompatible polymers and conjugation of targeting ligands are highlighted as essential for improving stability, circulation, targeting, and interaction with biological systems. The review summarizes how controlled synthesis and tailored surface chemistries influence particle size, magnetic properties, colloidal stability, and biodistribution—attributes that directly affect imaging contrast, therapeutic payload delivery, and safety profiles.
Strategies to achieve selective accumulation and controlled payload release are a central focus. Approaches discussed include:
These strategies are presented as complementary routes to improve antitumoral efficacy while reducing off-target effects and systemic toxicity.
Magnetic iron oxide nanoparticles have direct relevance to magnetic resonance imaging (MRI) as contrast agents and as components of image-guided therapeutic workflows. The review discusses advances in MRI applications, image-guided therapy, and multimodal therapy paradigms that leverage the dual diagnostic and therapeutic capabilities of SPION and USPION. By furnishing both imaging contrast and therapeutic functionality, these nanoplatforms support real-time monitoring of distribution and response, which is integral to theranostic concepts and personalized treatment planning.
Despite promising preclinical and early translational data, several barriers to clinical adoption are underscored. The review identifies key challenges including scalable manufacturing processes, demonstration of long-term safety, and regulatory considerations that must be addressed for clinical translation. Specific details such as quantitative safety data, regulatory pathways, or scale-up methodologies were not reported in the abstract and would require consulting the full text for comprehensive coverage.
The authors conclude that SPION- and USPION-based magnetic nanoplatforms represent a promising strategy for precision oncology. By combining diagnostic, therapeutic, and monitoring functions on a single nanoplatform, these materials can potentially improve targeting, enable image-guided interventions, and reduce off-target toxicity. The review emphasizes that continued advances in synthesis, surface modification, targeted delivery strategies, and careful attention to translation barriers are needed to facilitate the movement of magnetic nanomedicine toward personalized cancer treatment.
The review lists core keywords that reflect its scope: Anti-tumoral; Fe(3)O(4); Maghemite; Superparamagnetic Iron Oxide Nanoparticles (SPION); Targeted and controlled delivery; Ultrasmall Superparamagnetic Iron Oxide Nanoparticles (USPION). The article is presented as a review of recent advances and critical discussion of clinically relevant theranostic applications and translational challenges.
This summary is based on the PubMed abstract and bibliographic metadata for the review article. Detailed experimental data, specific synthesis protocols, preclinical or clinical study results, and quantitative safety or regulatory information were not included in the abstract and are not available in the provided source text. For in-depth technical or clinical details, consulting the full article is necessary.